Iceland· IS-EU/1/07/418/001-005
Celsentri
A maraviroc product containing maravirocum inn, registered in Iceland by ViiV Healthcare BV. The same ATC class is registered in 15 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Maraviroc is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AX09 (maraviroc), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Maraviroc · ATC J05AX09
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of maraviroc costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), the median price runs from $25.28 in France to $84.16 in United States — a ×3.3 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Maraviroc · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- US United States$84.16 (acquisition cost)
- CH Switzerland$55.16
- FR France$25.28
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Maravirocum INN
- Manufacturer
- ViiV Healthcare BV
- Country
- Iceland (IS)
- ATC code
- J05AX09
- ATC class
- Maraviroc
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
143 interactions on record for maraviroc.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Maraviroc · interactions on record
143 records
- 14 severe
- 129 moderate
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- CeritinibL01ED02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Maraviroc in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesMaravirocCamber Pharmaceuticals, Inc.
- CzechiaCELSENTRIViiV Healthcare BV, Amersfoort
- NetherlandsCelsentri 150 mg, filmomhulde tablettenViiV healthcare B.V.
- SpainCELSENTRI 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULAViiv Healthcare B.V.
- FinlandCELSENTRIViiV Healthcare BV
- FranceCELSENTRI 150 mg, comprimé pelliculéVIIV HEALTHCARE UK (ROYAUME-UNI)
- IrelandCelsentri 150 mg Film-coated tabletViiV Healthcare BV
- SwitzerlandCelsentri
Authorised across Europe · EMA
The same active substance is authorised in 10 EEA countries. Names it is sold under:
- Austria · Maraviroc
- Germany · Maraviroc, Maraviroc Amarox
- Spain · Maraviroc Tarbis, Maraviroc Waymade
- France · Maraviroc, Maraviroc Amarox
- United Kingdom (Northern Ireland) · Maraviroc Amarox Limited, Maraviroc Waymade
- Italy · Maraviroc Waymade
- Liechtenstein · Celsentri
- Netherlands · Maraviroc, Maraviroc Amarox
- Norway · Celsentri
- Portugal · Maraviroc
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b3bd0be7-07c2-4ff5-a652-8cb6f9291f34 GET /v1/drugs/b3bd0be7-07c2-4ff5-a652-8cb6f9291f34?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "J05AX09",
"marketed": false,
"strength": "150 mg",
"ma_number": "EU/1/07/418/001-005",
"substance": "Maravirocum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í smitsjúkdómum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "39368"
}See everything about maraviroc.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.